Ofthese agents, ABT-737, a BH3 mimetic that antagonizes BCL-2, BCL-XL, andBCL-w, demonstrated remarkable single-agent efficacy against AML in preclinicalstudies2. Here, BCL2 is linked to acute myeloid leukemia.